摘要
目的探究奥沙利铂所致不良反应/事件(ADR/ADE)的特点以及规律,为临床安全合理用药提供依据。方法采用回顾性研究方法,对2012年1月—2018年12月湖北省药品(医疗器械)不良反应监测中心收集的1627例奥沙利铂所致ADR/ADE报告,按性别、年龄、给药途径、ADR/ADE发生的时间、临床表现等进行统计分析。结果奥沙利铂所致ADR/ADE中,男女比例为1.32:1,患者年龄集中分布在41~80岁(92.87%);以静脉给药为主;患者多在用药1~24 h和1~7 d发生ADR/ADE;涉及多种系统,主要为消化系统损伤、中枢及外周神经系统损伤、血液系统损伤以及变态反应等。结论奥沙利铂所致ADR/ADE较为常见,并可产生严重器官损伤,临床用药应密切监测患者用药情况,给予相应处理措施,提高用药安全性。
Objective To explore the characteristics and patterns of oxaliplatin(OXA)induced adverse reactions/events(ADR/ADE),so as to provide a basis for the safe and rational drug use in clinic.Methods Retrospective study was conducted on 1627 cases of adverse reactions caused by OXA,which were collected in Hubei Provincial Drug(Medical Devices)Adverse Reactions Monitoring Center from January 2012 to December 2018.Statistical analysis was carried out according to gender,age,route of administration,time of occurrence of ADR/ADE,and clinical manifestations.Results In OXA-induced ADR/ADE cases,the male-female ratio was 1.32:1,and the age of the patients was mainly distributed between 41 and 80 years old(92.87%).Most of OXA-induced ADR/ADE occurred mainly from intravenous administration.Most patients developed ADR/ADE at 1-24 h and 1-7 d after the drug administration.OXA-induced ADR/ADE involved various systems,including digestive system injury,central and peripheral nervous system injury,blood system injury,and allergic reactions.Conclusion OXA-induced ADR/ADE was common in clinic,and could cause severe organ injury.Clinical medication should be closely monitored in patients,and appropriate treatment measures should be taken to improve the safety of medication.
作者
钟巧妮
李敏
上官小芳
赵丽
程似锦
张程亮
ZHONG Qiaoni;LI Min;SHANGGUAN Xiaofang;ZHAO Li;CHENG Sijin;ZHANG Chengliang(Zhongnan Hospital of Wuhan University,Wuhan 430071,China;Department of Pharmacy,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;School of pharmacy,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Hubei Center for ADR/ADE Monitoring,Wuhan 430071,China;Department of Medicine and Nursing,Changjiang Polytechnic,Wuhan 430064,China)
出处
《医药导报》
CAS
北大核心
2020年第2期239-243,共5页
Herald of Medicine
基金
湖北省药品(医疗器械)不良反应监测中心课题(20160422)
华中科技大学同济医学院研究型临床医师资助计划(5001540076)
